Sommaire

• • ·Editorial Board

    Page :i

    
• • ·TB vaccines for the World

    Page :1-6

    R. Glyn Hewinson

    Résumé Résumé Plan Plan
• • ·The tuberculosis vaccine challenge

    Page :7-12

    Michael J. Brennan

    Résumé Résumé Plan Plan
• • ·Mouse and guinea pig models for testing new tuberculosis vaccines

    Page :13-17

    Ian M. Orme

    Résumé Résumé Plan Plan
• • ·Cattle as a model for development of vaccines against human tuberculosis

    Page :19-24

    Bryce M. Buddle, Margot A. Skinner, D. Neil Wedlock, Geoffrey W. de Lisle, H. Martin Vordermeier, R. Glyn Hewinson

    Résumé Résumé Plan Plan
• • ·NIH pre-clinical screening program: overview and current status

    Page :25-28

    Angelo Izzo, Lise Brandt, Todd Lasco, Anna-Paula Kipnis, Ian Orme

    Résumé Résumé Plan Plan  
• • ·Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis

    Page :29-38

    Ann Williams, Graham J. Hatch, Simon O. Clark, Karen E. Gooch, Kim A. Hatch, Graham A. Hall, Kris Huygen, Tom H.M. Ottenhoff, Kees L.M.C. Franken, Peter Andersen, T. Mark Doherty, Stefan H.E. Kaufmann, Leander Grode, Peter Seiler, Carlos Martin, Brigitte Gicquel, Stewart T. Cole, Priscille Brodin, Alexander S. Pym, Wilfried Dalemans, Joe Cohen, Yves Lobet, Nilu Goonetilleke, Helen McShane, Adrian Hill, Tanya Parish, Debbie Smith, Neil G. Stoker, Douglas B. Lowrie, Gunilla Källenius, Stefan Svenson, Andrzej Pawlowski, Karen Blake, Philip D. Marsh

    Résumé Résumé Plan Plan  
• • ·Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues

    Page :39-46

    Sharon S. Rowland, Ronald L. Mayner, Lewellys Barker

    Résumé Résumé Plan Plan  
• • ·Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

    Page :47-52

    Helen McShane, Ansar A. Pathan, Clare R. Sander, Nilu P. Goonetilleke, Helen A. Fletcher, Adrian V.S. Hill

    Résumé Résumé Plan Plan
• • ·Control of human host immunity to mycobacteria

    Page :53-64

    Tom H.M. Ottenhoff, Frank A.W. Verreck, Marieke A. Hoeve, Esther van de Vosse

    Résumé Résumé Plan Plan  
• • ·Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice

    Page :65-72

    T.V. Radaeva, B.V. Nikonenko, V.V. Mischenko, M.M. Averbakh, A.S. Apt

    Résumé Résumé Plan Plan  
• • ·The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium

    Page :73-79

    G.W. de Lisle, B.J. Wards, B.M. Buddle, D.M. Collins

    Résumé Résumé Plan Plan  
• • ·Time course of mycobacterial infection of dendritic cells in the lungs of intranasally infected mice

    Page :81-88

    R. Reljic, C. Di Sano, C. Crawford, F. Dieli, S. Challacombe, J. Ivanyi

    Résumé Résumé Plan Plan  
• • ·Cell-mediated immune responses in children towards secreted proteins of Mycobacterium bovis BCG

    Page :89-93

    H. Surekha Rani, V. Vijaya Lakshmi, G. Sumanlatha, K.J.R. Murthy

    Résumé Résumé Plan Plan
• • ·Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes

    Page :95-105

    J. McMurry, H. Sbai, M.L. Gennaro, E.J. Carter, W. Martin, A.S. De Groot

    Résumé Résumé Plan Plan
• • ·Nasal boost with adjuvanted heat-killed BCG or arabinomannan–protein conjugate improves primary BCG-induced protection in C57BL/6 mice

    Page :107-114

    M. Haile, B. Hamasur, T. Jaxmar, D. Gavier-Widen, M.A. Chambers, B. Sanchez, U. Schröder, G. Källenius, S.B. Svenson, A. Pawlowski

    Résumé Résumé Plan Plan  
• • ·A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis

    Page :115-126

    Mauricio Castañon-Arreola, Yolanda López-Vidal, Clara Espitia-Pinzón, Rogelio Hernández-Pando

    Résumé Résumé Plan Plan